Engineered GPCR Enhances CAR-NK Therapy for Solid Tumors

Researchers have engineered the OR7A10 G protein-coupled receptor (GPCR) to enhance the effectiveness of chimeric antigen receptor natural killer (CAR-NK) cell therapy against solid tumors. This advancement, detailed in an author correction published in Nature on July 13, 2026, addresses a critical limitation in current CAR-NK therapies, which often struggle to penetrate and persist within the complex tumor microenvironment.

The engineered OR7A10 GPCR is designed to improve CAR-NK cell homing and activation. By modifying the receptor, the CAR-NK cells are better equipped to recognize and engage with tumor cells, leading to increased cytotoxicity. This targeted approach aims to overcome the immunosuppressive nature of solid tumors, which frequently leads to the rejection or dysfunction of therapeutic immune cells.

This development represents a significant step forward in the field of cancer immunotherapy. CAR-NK cell therapy holds promise due to NK cells' inherent ability to kill cancer cells without requiring prior sensitization, unlike T cells. However, their application in solid tumors has been hampered by poor infiltration and survival. The OR7A10 GPCR engineering offers a potential solution to these challenges, paving the way for more robust and effective treatments for patients with solid malignancies.